SABCS 2022

Conference Coverage

Platinum Chemo “Should Be Standard” for Younger Patients With TNBC

Cemiplimab Plus REGN3767 and Chemo Shows Promise for HER2- Breast Cancer

Germline PVs in BRCA1/2, CHEK2 Linked to Higher Risk of Contralateral Breast Cancer

Duration of Prior CDK4/6 Inhibitor Treatment Tied to PFS With Elacestrant

Ribociclib Plus ET Outperforms Chemo in HR+/HER2− Advanced Breast Cancer

Interrupting ET for Pregnancy Does Not Seem to Affect Short-Term Outcomes of Breast Cancer

Palbociclib Does Not Improve PFS After Progression on CDK4/6 Inhibitors, ET

Camizestrant Improves PFS vs Fulvestrant in ER+/HER2- Advanced Breast Cancer

Trastuzumab Deruxtecan Elicits Responses in HER2-Low Early Breast Cancer

Capivasertib Improves PFS in AI-Resistant, HR+/HER2– Advanced Breast Cancer

Older Patients With Metastatic Breast Cancer Often Do Not Receive First-Line Systemic Therapy

Breast Cancer Index Predicts Response to Ovarian Function Suppression

T-DXd Improves Survival vs T-DM1 in HER2+ Advanced Breast Cancer

TAILORx Update Confirms Intermediate-Risk Breast Cancer Patients Can Forgo Chemotherapy

Abemaciclib Provides Long-Term Benefits in HR+, HER2- Breast Cancer

Trastuzumab Deruxtecan Improves PFS and OS in HER2+ Advanced Breast Cancer

Adding Everolimus to Adjuvant ET Does Not Improve Survival in High-Risk HR+/HER2- Breast Cancer

DFS Improved With AIs vs Tamoxifen in HR+, HER2- Early Breast Cancer

Adding Chemo to Endocrine Therapy Increases Cognitive Impairment in HR+, HER2- Breast Cancer

Investigating Racial Disparities in HR+, HER2- Breast Cancer